Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
Titel:
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
Auteur:
Baljevic, Muhamed Zaman, Shadia Baladandayuthapani, Veerabhadran Lin, Yan Heather Partovi, Claudia Morales de Berkova, Zuzana Amini, Behrang Thomas, Sheeba K. Shah, Jatin J. Weber, Donna M. Fu, Min Cleeland, Charles S. Wang, Xin Shelley Stellrecht, Christine M. Davis, Richard E. Gandhi, Varsha Orlowski, Robert Z.